Publikationen (13) Publikationen von IZASKUN ZEBERIO ETXETXIPIA

2023

  1. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

2022

  1. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

2020

  1. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 2, pp. 323-332

  2. Identification of recurrent mutations in the microrna‐binding sites of b‐cell lymphoma‐ associated genes in follicular lymphoma

    International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-12

  3. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542

2017

  1. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 67-74

  2. Lehen mailako arretaren eta hematologiako kontsultaren arteko deribazio- eta kudeaketa-irizpideak

    Osagaiz: osasun-zientzien aldizkaria, Vol. 1, Núm. 2, pp. 43-51

2015

  1. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 6, pp. 971-983

  2. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT

    Bone Marrow Transplantation, Vol. 50, Núm. 3, pp. 438-443

  3. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant

    Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 663-670

2014

  1. A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: Favorably durable event-free survival in chemosensitive patients

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 3, pp. 354-360

2013

  1. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation

    Nature Medicine, Vol. 19, Núm. 3, pp. 372-377

2003

  1. Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease

    Haematologica, Vol. 88, Núm. 2, pp. 236-237